Immunosuppressive glycoforms of soluble CD52

Leonard Charles Harrison; Esther Bandala-Sanchez; Ethan David Goddard-Borger; Nicolle Hannah Packer; Abdulrahman Shathili

Immunosuppressive glycoforms of soluble CD52

Leonard Charles Harrison (Inventor), Esther Bandala-Sanchez (Inventor), Ethan David Goddard-Borger (Inventor), Nicolle Hannah Packer (Inventor), Abdulrahman Shathili (Inventor)

Research output: Patent

Abstract

The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has a-2,3-sialylated N-glycans, 0-glycosylation and a pl 5 of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

Original language	English
Patent number	AU2019201584
IPC	C07K 4/12,A61K 38/00,A61K 38/10,A61K 39/00,A61P 29/00,A61P 37/00
Priority date	7/03/19
Filing date	7/03/19
Publication status	Published - 19 Mar 2020

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=AU240329470

3 Patent

Immunosuppressive glycoforms of soluble CD52
Harrison, L. C., Bandala Sanchez, E., Goddard-Borger, E. D., Packer, N. H. & Mansour, S. A., 16 Jun 2022, (Submitted) IPC No. C07K 14/705, A61K 38/17, A61K 35/16, A61K 38/28, Patent No. US2022185864, Priority date 7 Mar 2019, Priority No. WO2019AU50197
Research output: Patent
Immunosuppressive glycoforms of soluble CD52
Harrison, L. C., Bandala-Sanchez, E., Goddard-Borger, E. D., Packer, N. H. & Mansour, S. A., 12 Jan 2022, (Submitted) IPC No. C07K 9/00, A61K 38/00, A61K 38/04, A61P 37/00, C07K 1/18, C07K 1/22, Patent No. EP3935073, Priority date 7 Mar 2019, Priority No. WO2019AU50197
Research output: Patent
Immunosuppressive glycoforms of soluble CD52
Harrison, L. C., Bandala-Sanchez, E., Goddard-Borger, E. D., Packer, N. H. & Mansour, S. A., 10 Sept 2020, (Submitted) IPC No. C07K 9/00 2006.1, C07K 1/22 2006.1, C07K 1/18 2006.1, A61P 37/00 2006.1, A61K 38/04 2006.1, Patent No. WO2020176921, Priority date 7 Mar 2019, Priority No. WO2019AU50197
Research output: Patent

Cite this

@misc{bfb339b2a34b42b387886af13810bbf5,

title = "Immunosuppressive glycoforms of soluble CD52",

abstract = "The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has a-2,3-sialylated N-glycans, 0-glycosylation and a pl 5 of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.",

author = "Harrison, {Leonard Charles} and Esther Bandala-Sanchez and Goddard-Borger, {Ethan David} and Packer, {Nicolle Hannah} and Abdulrahman Shathili",

year = "2020",

month = mar,

day = "19",

language = "English",

type = "Patent",

note = "AU2019201584; C07K 4/12,A61K 38/00,A61K 38/10,A61K 39/00,A61P 29/00,A61P 37/00",

}

TY - PAT

T1 - Immunosuppressive glycoforms of soluble CD52

AU - Harrison, Leonard Charles

AU - Bandala-Sanchez, Esther

AU - Goddard-Borger, Ethan David

AU - Packer, Nicolle Hannah

AU - Shathili, Abdulrahman

PY - 2020/3/19

Y1 - 2020/3/19

N2 - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has a-2,3-sialylated N-glycans, 0-glycosylation and a pl 5 of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

AB - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has a-2,3-sialylated N-glycans, 0-glycosylation and a pl 5 of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

M3 - Patent

M1 - AU2019201584

Y2 - 2019/03/07

ER -

Immunosuppressive glycoforms of soluble CD52

Abstract

Access to Document

Fingerprint

Research output